Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

30

Enrollment

NIH

Sponsor class

Stopped Other - Protocol amendment to clarify DLT language

Conditions

Astrocytoma, IDH-Mutant, Grade 2
Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant
Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant
Recurrent Astrocytoma, IDH-Mutant
Recurrent Astrocytoma, IDH-Mutant, Grade 3
Recurrent Astrocytoma, IDH-Mutant, Grade 4
Recurrent Glioblastoma, IDH-Wildtype

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
RADIATION: Intensity-Modulated Radiation Therapy
PROCEDURE: Magnetic Resonance Imaging
DRUG: Triapine

Sponsor

National Cancer Institute (NCI)